Hormone Replacement Therapy in Cancer Survivors – Review of the Literature
This 2019 review critically evaluates the safety and efficacy of hormone replacement therapy (HRT) in female cancer survivors. It categorizes tumors into three groups based on oncologic risk associated with HRT: (1) HRT is advantageous (e.g., endometrial cancer type I, cervical adenocarcinoma, hematologic malignancies), (2) HRT is neutral (e.g., BRCA1/2